Mark Mirkin focuses his practice on strategic corporate and securities counseling to emerging and high-growth companies, especially in the context of seed, early stage and venture capital financings, mergers and acquisitions, divestitures and IPOs. He has applied his voluminous knowledge of the startup landscape to help his clients in early stage financing transactions, particularly in private placements and public offerings of equity, debt and convertible securities. In this capacity, he has extensive experience advising companies in the life sciences, information technology, and clean technology industries in all aspects of corporate and securities law.
Mr. Mirkin has represented numerous biotech and medtech startups in launching their drug discoveries and medical devices, helping to navigate them through the FDA clinical trial process for new drug approval and to surmount the regulatory hurdles for medical devices. Many such companies have been spin-outs from universities' and research institutions' laboratories, benefiting along with infotech startups from Mr. Mirkin's extensive experience in the technology transfer process.
Prior to joining Rimon, Mr. Mirkin worked as a partner at Hicks, Motto & Ehrlich in Palm Beach Gardens, Florida, following a six year stint in Research Triangle Park, North Carolina. He has been a frequent speaker to university audiences of engineering, computer science and medical students on topics of corporate and securities law, especially venture financing for technology startups. He was honored to chair the inaugural Southeast Venture Conference, now in its 8th successful year.
Mr. Mirkin received his J.D. from Duke Law School and his B.A. in Economics cum laude from Duke University.
News, Events, & Insights
Rimon Deal Featured in DBR Daily Business Review
News January 06, 2016
Corporate Governance in the Lifecycle of a Pre-Sales Revenue Biotechnology Venture Destined for IPO Success
Insights August 14, 2014
Capital Structure Particulars in the Lifecycle of a Pre-Sales Revenue Biotechnology Venture Destined for IPO Success
Insights July 31, 2014
Introducing a New Drug Into the Marketplace in the Lifecycle of a Pre-Sales Revenue Biotechnology Venture Destined for IPO Success
Insights July 24, 2014
Success Protecting Intellectual Property in the Lifecycle of a Pre-Sales Revenue Biotechnology Venture Destined for IPO
Insights April 22, 2014
The FDA Drug Approval Process in the Lifecycle of a Pre-Sales Revenue Biotechnology Venture Destined for IPO Success
Insights February 25, 2014